Dr. Garon on Immunotherapy for Patients With NSCLC
Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer.
Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non—small cell lung cancer (NSCLC).
The addition of immunotherapy agents to the treatment landscape of NSCLC has led to a very exciting time for a disease originally not believed to be immunogenic, Garon explains.
Today, evidence suggests that such agents could become the frontline choice for select patients with stage IV disease versus standard chemotherapy.
<<<
Related Videos
Related Content
